<DOC>
	<DOCNO>NCT02060604</DOCNO>
	<brief_summary>The addition anti-inflammatory agent could valid option control choroidal neovascularization , simply inhibit VEGF address neither multifactorial pathogenesis choroidal neovascularization underlie cause VEGF production .</brief_summary>
	<brief_title>Pilot Study Ranibizumab With Without Ketorolac Eyedrops Exudative Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1. ability provide write informed consent comply study assessment full duration study ; 2. age &gt; 40 year ; 3. presence treatmentna√Øve neovascular AMD visual acuity 20/25 20/200 Early Treatment Diabetic Retinopathy Study ( ETDRS ) chart . Inclusion criterion AMD neovascularisation , fluid , haemorrhage fovea . 1. previous intravitreal treatment ; 2. previous laser treatment study eye ; 3. myopia &gt; 7 dioptre study eye ; 4. concurrent eye disease study eye could compromise visual acuity ( eg , diabetic retinopathy , advanced glaucoma ) ; 5. concurrent corneal epithelial disruption condition would affect ability cornea heal ; 6. know sensitivity component formulation investigation .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>ketorolac</keyword>
	<keyword>NSAIDs</keyword>
	<keyword>wet macular degeneration</keyword>
	<keyword>choroidal neovascularization</keyword>
</DOC>